- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY 3.70 Å
- Oligo State
- hetero-3-2-2-mer
- Ligands
- 10 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 1 x NAG- NAG- BMA- FUC: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG- BMA- MAN- MAN- FUC: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN-FUC.12: 14 residues within 4Å:- Chain C: G.358, F.361, N.362, V.386, L.387
- Chain D: Y.32, R.98, G.112, D.115
- Chain E: L.47, Y.50, R.55, T.57, G.58
4 PLIP interactions:3 interactions with chain D, 1 interactions with chain E- Hydrogen bonds: D:Y.32, D:R.98, D:D.115, E:G.58
- Hydrophobic interactions: E:L.47, E:Y.50
- 35 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.13: 4 residues within 4Å:- Chain A: Y.47, T.48, N.49, N.80
Ligand excluded by PLIPNAG.14: 4 residues within 4Å:- Chain A: N.141, A.142, T.143, N.144
Ligand excluded by PLIPNAG.15: 2 residues within 4Å:- Chain A: N.253, T.255
Ligand excluded by PLIPNAG.16: 3 residues within 4Å:- Chain A: N.299, E.300, N.301
Ligand excluded by PLIPNAG.17: 2 residues within 4Å:- Chain A: N.350, Q.599
Ligand excluded by PLIPNAG.18: 1 residues within 4Å:- Chain A: N.622
Ligand excluded by PLIPNAG.19: 2 residues within 4Å:- Chain A: N.635, Q.663
Ligand excluded by PLIPNAG.20: 2 residues within 4Å:- Chain A: H.674, N.676
Ligand excluded by PLIPNAG.21: 2 residues within 4Å:- Chain A: N.728, G.1150
Ligand excluded by PLIPNAG.22: 4 residues within 4Å:- Chain A: A.725, E.1091, K.1092, N.1093
Ligand excluded by PLIPNAG.23: 3 residues within 4Å:- Chain A: I.1151, V.1152, N.1153
Ligand excluded by PLIPNAG.24: 3 residues within 4Å:- Chain B: F.78, S.79, N.80
Ligand excluded by PLIPNAG.25: 3 residues within 4Å:- Chain B: N.141, A.142, T.143
Ligand excluded by PLIPNAG.26: 1 residues within 4Å:- Chain B: N.253
Ligand excluded by PLIPNAG.27: 3 residues within 4Å:- Chain B: N.299, E.300, N.301
Ligand excluded by PLIPNAG.28: 4 residues within 4Å:- Chain B: P.349, N.350, P.598, Q.599
Ligand excluded by PLIPNAG.29: 4 residues within 4Å:- Chain B: F.357, G.358, F.361, N.362
Ligand excluded by PLIPNAG.30: 1 residues within 4Å:- Chain B: N.622
Ligand excluded by PLIPNAG.31: 2 residues within 4Å:- Chain B: N.635, T.637
Ligand excluded by PLIPNAG.32: 2 residues within 4Å:- Chain B: H.674, N.676
Ligand excluded by PLIPNAG.33: 2 residues within 4Å:- Chain B: N.728, G.1150
Ligand excluded by PLIPNAG.34: 3 residues within 4Å:- Chain B: N.736, N.938, L.941
Ligand excluded by PLIPNAG.35: 4 residues within 4Å:- Chain B: A.725, E.1091, K.1092, N.1093
Ligand excluded by PLIPNAG.36: 1 residues within 4Å:- Chain B: N.184
Ligand excluded by PLIPNAG.37: 4 residues within 4Å:- Chain C: Y.47, T.48, N.49, N.80
Ligand excluded by PLIPNAG.38: 4 residues within 4Å:- Chain C: N.141, A.142, T.143, N.144
Ligand excluded by PLIPNAG.39: 2 residues within 4Å:- Chain C: G.251, N.253
Ligand excluded by PLIPNAG.40: 2 residues within 4Å:- Chain C: N.299, N.301
Ligand excluded by PLIPNAG.41: 2 residues within 4Å:- Chain C: P.349, N.350
Ligand excluded by PLIPNAG.42: 2 residues within 4Å:- Chain C: N.622, T.623
Ligand excluded by PLIPNAG.43: 2 residues within 4Å:- Chain C: N.635, T.637
Ligand excluded by PLIPNAG.44: 2 residues within 4Å:- Chain C: H.674, N.676
Ligand excluded by PLIPNAG.45: 2 residues within 4Å:- Chain C: N.728, G.1150
Ligand excluded by PLIPNAG.46: 4 residues within 4Å:- Chain C: A.725, E.1091, K.1092, N.1093
Ligand excluded by PLIPNAG.47: 1 residues within 4Å:- Chain C: N.184
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Pinto, D. et al., Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature (2020)
- Release Date
- 2020-05-27
- Peptides
- spike glycoprotein: ABC
S309 neutralizing antibody heavy chain: DF
S309 neutralizing antibody light chain: EG - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
CD
HF
DE
LG
E
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY 3.70 Å
- Oligo State
- hetero-3-2-2-mer
- Ligands
- 10 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 1 x NAG- NAG- BMA- FUC: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG- BMA- MAN- MAN- FUC: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose
- 35 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Pinto, D. et al., Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature (2020)
- Release Date
- 2020-05-27
- Peptides
- spike glycoprotein: ABC
S309 neutralizing antibody heavy chain: DF
S309 neutralizing antibody light chain: EG - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
CD
HF
DE
LG
E